{"pmid":32381643,"title":"Comparison of Two High-Throughput Reverse Transcription-Polymerase Chain Reaction Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2.","text":["Comparison of Two High-Throughput Reverse Transcription-Polymerase Chain Reaction Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as the cause of a worldwide pandemic. Many commercial SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) assays have received Emergency Use Authorization from the United States Food and Drug Administration. However, there are limited data describing their performance, in particular the performance of high-throughput SARS-CoV-2 RT-PCR systems. We analyzed the diagnostic performance of two high-throughput systems: cobas 6800 and Panther Fusion, and their associated RT-PCR assays with a collection of 389 nasopharyngeal specimens. The overall percent agreement between the platforms was 96.4% (375/389). Cohen's kappa analysis rated the strength of agreement between the two platforms as \"almost perfect\" (kappa = 0.922; standard error, 0.051). Furthermore, there was no significant difference between corresponding cycle threshold values generated on the two systems (P value = 0.88; Student's t test). Taken together, these data imply both platforms can be considered comparable in terms of their clinical performance. We believe this information will be useful for those who have already adopted these platforms or are seeking to implement high-throughput RT-PCR testing to stem the SARS-CoV-2 pandemic.","J Clin Microbiol","Craney, Arryn R","Velu, Priya","Satlin, Michael J","Fauntleroy, Kathy A","Callan, Katrina","Robertson, Amy","La Spina, Marisa","Lei, Beryl","Chen, Anqi","Alston, Tricia","Rozman, Anna","Loda, Massimo","Rennert, Hanna","Cushing, Melissa","Westblade, Lars F","32381643"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as the cause of a worldwide pandemic. Many commercial SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) assays have received Emergency Use Authorization from the United States Food and Drug Administration. However, there are limited data describing their performance, in particular the performance of high-throughput SARS-CoV-2 RT-PCR systems. We analyzed the diagnostic performance of two high-throughput systems: cobas 6800 and Panther Fusion, and their associated RT-PCR assays with a collection of 389 nasopharyngeal specimens. The overall percent agreement between the platforms was 96.4% (375/389). Cohen's kappa analysis rated the strength of agreement between the two platforms as \"almost perfect\" (kappa = 0.922; standard error, 0.051). Furthermore, there was no significant difference between corresponding cycle threshold values generated on the two systems (P value = 0.88; Student's t test). Taken together, these data imply both platforms can be considered comparable in terms of their clinical performance. We believe this information will be useful for those who have already adopted these platforms or are seeking to implement high-throughput RT-PCR testing to stem the SARS-CoV-2 pandemic."],"journal":"J Clin Microbiol","authors":["Craney, Arryn R","Velu, Priya","Satlin, Michael J","Fauntleroy, Kathy A","Callan, Katrina","Robertson, Amy","La Spina, Marisa","Lei, Beryl","Chen, Anqi","Alston, Tricia","Rozman, Anna","Loda, Massimo","Rennert, Hanna","Cushing, Melissa","Westblade, Lars F"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381643","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/JCM.00890-20","topics":["Diagnosis"],"weight":1,"_version_":1666419683355525120,"score":9.490897,"similar":[{"pmid":32383179,"title":"Comparison of SARS-CoV-2 Detection from Nasopharyngeal Swab Samples by the Roche cobas(R) 6800 SARS-CoV-2 Test and a Laboratory-Developed Real-Time RT-PCR test.","text":["Comparison of SARS-CoV-2 Detection from Nasopharyngeal Swab Samples by the Roche cobas(R) 6800 SARS-CoV-2 Test and a Laboratory-Developed Real-Time RT-PCR test.","The urgent need to implement and rapidly expand testing for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has led to development of multiple assays. How these tests perform relative to one another is poorly understood. We evaluated the concordance between the Roche Diagnostics cobas(R) 6800 SARS-CoV-2 Test and a laboratory- developed Real-Time RT-PCR test (LDT) based on a modified Centers for Disease Control and Prevention (CDC) protocol, for the detection of SARS-CoV-2 in samples submitted to the Clinical Laboratories of the Mount Sinai Health System. 1006 Nasopharyngeal swabs in universal transport medium from persons under investigation were tested for SARS-CoV-2 as part of routine clinical care using the cobas SARS-CoV2 test with subsequent evaluation by the LDT. Cycle threshold values were analyzed and interpreted as either positive ('Detected' or 'Presumptive Positive'), negative ('Not Detected'), inconclusive, or invalid. Statistical analysis was performed using GraphPad Prism 8. The cobas SARS-CoV2 test reported 706 positives and 300 negatives. The LDT reported 640 positives, 323 negatives, 34 inconclusive, and 9 invalids. When excluding inconclusive and invalid results, the overall percent agreement between the two platforms was 95.8%. Cohen's kappa coefficient (kappa) was 0.904 (95 % CI 0.875-0.933), suggesting almost perfect agreement between both platforms. An overall discordance rate of 4.2% between the two systems may reflect differences in primer sequences, assay limit of detection, or other factors, highlighting the importance of comparing the performance of different testing platforms. This article is protected by copyright. All rights reserved.","J Med Virol","Pujadas, Elisabet","Ibeh, Nnaemeka","Hernandez, Matthew M","Waluszko, Aneta","Sidorenko, Tatyana","Flores, Vanessa","Shiffrin, Biana","Chiu, Numthip","Young-Francois, Alicia","Nowak, Michael D","Paniz-Mondolfi, Alberto E","Sordillo, Emilia M","Cordon-Cardo, Carlos","Houldsworth, Jane","Gitman, Melissa R","32383179"],"abstract":["The urgent need to implement and rapidly expand testing for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has led to development of multiple assays. How these tests perform relative to one another is poorly understood. We evaluated the concordance between the Roche Diagnostics cobas(R) 6800 SARS-CoV-2 Test and a laboratory- developed Real-Time RT-PCR test (LDT) based on a modified Centers for Disease Control and Prevention (CDC) protocol, for the detection of SARS-CoV-2 in samples submitted to the Clinical Laboratories of the Mount Sinai Health System. 1006 Nasopharyngeal swabs in universal transport medium from persons under investigation were tested for SARS-CoV-2 as part of routine clinical care using the cobas SARS-CoV2 test with subsequent evaluation by the LDT. Cycle threshold values were analyzed and interpreted as either positive ('Detected' or 'Presumptive Positive'), negative ('Not Detected'), inconclusive, or invalid. Statistical analysis was performed using GraphPad Prism 8. The cobas SARS-CoV2 test reported 706 positives and 300 negatives. The LDT reported 640 positives, 323 negatives, 34 inconclusive, and 9 invalids. When excluding inconclusive and invalid results, the overall percent agreement between the two platforms was 95.8%. Cohen's kappa coefficient (kappa) was 0.904 (95 % CI 0.875-0.933), suggesting almost perfect agreement between both platforms. An overall discordance rate of 4.2% between the two systems may reflect differences in primer sequences, assay limit of detection, or other factors, highlighting the importance of comparing the performance of different testing platforms. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Pujadas, Elisabet","Ibeh, Nnaemeka","Hernandez, Matthew M","Waluszko, Aneta","Sidorenko, Tatyana","Flores, Vanessa","Shiffrin, Biana","Chiu, Numthip","Young-Francois, Alicia","Nowak, Michael D","Paniz-Mondolfi, Alberto E","Sordillo, Emilia M","Cordon-Cardo, Carlos","Houldsworth, Jane","Gitman, Melissa R"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383179","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25988","keywords":["rna extraction","sars","coronavirus"],"locations":["kappa"],"topics":["Diagnosis"],"weight":1,"_version_":1666419683348185088,"score":429.09314},{"pmid":32353760,"pmcid":"PMC7195328","title":"Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.","text":["Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.","BACKGROUND: Numerous nucleic acid amplification assays have recently received emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection, and there is a need to assess their test performance relative to one another. OBJECTIVES: The aim of this study was to compare the test performance of the Hologic Panther Fusion SARS-CoV-2 assay targeting two regions of open reading frame 1ab (ORF1ab) to a high complexity molecular-based, laboratory-developed EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene. STUDY DESIGN: We performed a diagnostic comparison study by testing nasopharyngeal samples on the two assays. Assay agreement was assessed by overall percent agreement and Cohen's kappa coefficient. RESULTS: A total of 184 nasopharyngeal samples were tested using the two assays, of which 180 showed valid results and were included for the comparative analysis. Overall percent agreement between the assays was 98.3 % (95 % confidence interval (CI) 95.2-99.7) and kappa coefficient was 0.97 (95 % CI 0.93-1.0). One sample was detected on the SHC laboratory developed test (LDT) and not on the Panther Fusion, and had a Ct of 35.9. Conversely, 2 samples were detected on the Panther Fusion and not on the LDT, and had Ct values of 37.2 and 36.6. CONCLUSION: The Panther Fusion SARS-CoV-2 assay and the SHC LDT perform similarly on clinical nasopharyngeal swab specimens. Other considerations, including reagent availability, turnaround time, labor requirements, cost and instrument throughput should guide the decision of which assay to perform.","J Clin Virol","Hogan, Catherine A","Sahoo, Malaya K","Huang, ChunHong","Garamani, Natasha","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A","32353760"],"abstract":["BACKGROUND: Numerous nucleic acid amplification assays have recently received emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection, and there is a need to assess their test performance relative to one another. OBJECTIVES: The aim of this study was to compare the test performance of the Hologic Panther Fusion SARS-CoV-2 assay targeting two regions of open reading frame 1ab (ORF1ab) to a high complexity molecular-based, laboratory-developed EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene. STUDY DESIGN: We performed a diagnostic comparison study by testing nasopharyngeal samples on the two assays. Assay agreement was assessed by overall percent agreement and Cohen's kappa coefficient. RESULTS: A total of 184 nasopharyngeal samples were tested using the two assays, of which 180 showed valid results and were included for the comparative analysis. Overall percent agreement between the assays was 98.3 % (95 % confidence interval (CI) 95.2-99.7) and kappa coefficient was 0.97 (95 % CI 0.93-1.0). One sample was detected on the SHC laboratory developed test (LDT) and not on the Panther Fusion, and had a Ct of 35.9. Conversely, 2 samples were detected on the Panther Fusion and not on the LDT, and had Ct values of 37.2 and 36.6. CONCLUSION: The Panther Fusion SARS-CoV-2 assay and the SHC LDT perform similarly on clinical nasopharyngeal swab specimens. Other considerations, including reagent availability, turnaround time, labor requirements, cost and instrument throughput should guide the decision of which assay to perform."],"journal":"J Clin Virol","authors":["Hogan, Catherine A","Sahoo, Malaya K","Huang, ChunHong","Garamani, Natasha","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353760","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jcv.2020.104383","keywords":["laboratory-developed test","panther fusion","qiasymphony","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495755747328,"score":406.86252},{"pmid":32277022,"title":"Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic.","text":["Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic.","Laboratories are currently witnessing extraordinary demand globally for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of SARS-CoV-2 infection. To meet diagnostic needs as the pandemic grows, the US Food and Drug Administration (FDA) recently granted several commercial SARS-CoV-2 tests Emergency Use Authorization (EUA), but manufacturer-independent evaluation data are scarce. We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2 (cobas) (Roche Molecular Systems, Branchburg, NJ), which received US FDA EUA on March 12, 2020. The comparator was a standardized 3-hour SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target RT-PCR, which our laboratory has routinely used since January 2020 (Corman VM et al. EuroSurveill 25 (3):2000045). Cobas and the comparator showed overall agreement of 98.1% and a kappa value of 0.95 on an in-house validation panel consisting of 217 well-characterized retrospective samples. Immediate prospective head-to-head comparative evaluation followed on 502 samples, and the diagnostic approaches showed overall percent agreement of 99.6% and a kappa value of 0.98. A good correlation (r (2) = 0.96) between cycle threshold values for SARS-CoV-2 specific targets obtained by cobas and the comparator was observed. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the UTM-RT system. Under the extraordinary circumstances that laboratories are facing worldwide, a safe diagnostic platform switch is feasible in only 48 hours and in the midst of the COVID-19 pandemic if carefully planned and executed.","J Clin Microbiol","Poljak, Mario","Korva, Misa","Knap Gasper, Natasa","Fujs Komlos, Kristina","Sagadin, Martin","Ursic, Tina","Avsic Zupanc, Tatjana","Petrovec, Miroslav","32277022"],"abstract":["Laboratories are currently witnessing extraordinary demand globally for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of SARS-CoV-2 infection. To meet diagnostic needs as the pandemic grows, the US Food and Drug Administration (FDA) recently granted several commercial SARS-CoV-2 tests Emergency Use Authorization (EUA), but manufacturer-independent evaluation data are scarce. We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2 (cobas) (Roche Molecular Systems, Branchburg, NJ), which received US FDA EUA on March 12, 2020. The comparator was a standardized 3-hour SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target RT-PCR, which our laboratory has routinely used since January 2020 (Corman VM et al. EuroSurveill 25 (3):2000045). Cobas and the comparator showed overall agreement of 98.1% and a kappa value of 0.95 on an in-house validation panel consisting of 217 well-characterized retrospective samples. Immediate prospective head-to-head comparative evaluation followed on 502 samples, and the diagnostic approaches showed overall percent agreement of 99.6% and a kappa value of 0.98. A good correlation (r (2) = 0.96) between cycle threshold values for SARS-CoV-2 specific targets obtained by cobas and the comparator was observed. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the UTM-RT system. Under the extraordinary circumstances that laboratories are facing worldwide, a safe diagnostic platform switch is feasible in only 48 hours and in the midst of the COVID-19 pandemic if carefully planned and executed."],"journal":"J Clin Microbiol","authors":["Poljak, Mario","Korva, Misa","Knap Gasper, Natasa","Fujs Komlos, Kristina","Sagadin, Martin","Ursic, Tina","Avsic Zupanc, Tatjana","Petrovec, Miroslav"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277022","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1128/JCM.00599-20","locations":["cobas","Branchburg","US","Cobas","kappa","kappa","cobas","cobas"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491639037953,"score":400.79105},{"pmid":32350048,"title":"Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in Clinical Laboratories.","text":["Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in Clinical Laboratories.","Multiple laboratory developed tests and commercially available assays have emerged to meet diagnostic needs related to the SARS-CoV-2 pandemic. To date, there is limited comparison data for these different testing platforms. We compared the analytical performance of a laboratory developed test (LDT) developed in our clinical laboratory based on CDC primer sets and four commercially available, FDA emergency use authorized assays for SARS-CoV-2 (Cepheid, DiaSorin, Hologic Panther, and Roche Cobas) on a total of 169 nasopharyngeal swabs. The LDT and Cepheid Xpert Xpress SARS-CoV-2 assays were the most sensitive assays for SARS-CoV-2 with 100% agreement across specimens. The Hologic Panther Fusion, DiaSorin Simplexa, and Roche Cobas 6800 only failed to detect positive specimens near the limit of detection of our CDC-based LDT assay. All assays were 100% specific, using our CDC-based LDT as the gold standard. Our results provide initial test performance characteristics for SARS-CoV-2 RT-PCR and highlight the importance of having multiple viral detection testing platforms available in a public health emergency.","J Clin Microbiol","Lieberman, Joshua A","Pepper, Gregory","Naccache, Samia N","Huang, Meei-Li","Jerome, Keith R","Greninger, Alexander L","32350048"],"abstract":["Multiple laboratory developed tests and commercially available assays have emerged to meet diagnostic needs related to the SARS-CoV-2 pandemic. To date, there is limited comparison data for these different testing platforms. We compared the analytical performance of a laboratory developed test (LDT) developed in our clinical laboratory based on CDC primer sets and four commercially available, FDA emergency use authorized assays for SARS-CoV-2 (Cepheid, DiaSorin, Hologic Panther, and Roche Cobas) on a total of 169 nasopharyngeal swabs. The LDT and Cepheid Xpert Xpress SARS-CoV-2 assays were the most sensitive assays for SARS-CoV-2 with 100% agreement across specimens. The Hologic Panther Fusion, DiaSorin Simplexa, and Roche Cobas 6800 only failed to detect positive specimens near the limit of detection of our CDC-based LDT assay. All assays were 100% specific, using our CDC-based LDT as the gold standard. Our results provide initial test performance characteristics for SARS-CoV-2 RT-PCR and highlight the importance of having multiple viral detection testing platforms available in a public health emergency."],"journal":"J Clin Microbiol","authors":["Lieberman, Joshua A","Pepper, Gregory","Naccache, Samia N","Huang, Meei-Li","Jerome, Keith R","Greninger, Alexander L"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350048","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00821-20","topics":["Diagnosis"],"weight":1,"_version_":1666138495745261568,"score":382.1856},{"pmid":32461285,"title":"Comparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal Specimens.","text":["Comparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal Specimens.","Background: Several point-of-care (POC) molecular tests have received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for diagnosis of SARS-CoV-2. The test performance characteristics of the Accula (Mesa Biotech) SARS-CoV-2 POC test need to be evaluated to inform its optimal use.Objectives: The aim of this study was to assess test performance of the Accula SARS-CoV-2 test.Study design: The performance of the Accula test was assessed by comparing results of 100 nasopharyngeal swab samples previously characterized by the Stanford Health Care EUA laboratory-developed test (SHC-LDT) targeting the envelope (E) gene. Assay concordance was assessed by overall percent agreement, positive percent agreement (PPA), negative percent agreement (NPA), and Cohen's kappa coefficient.Results: Overall percent agreement between the assays was 84.0% (95% confidence interval [CI] 75.3 to 90.6%), PPA was 68.0% (95% CI 53.3 to 80.5%) and the kappa coefficient was 0.68 (95% CI 0.54 to 0.82). Sixteen specimens detected by the SHC-LDT were not detected by the Accula test, and showed low viral load burden with a median cycle threshold value of 37.7. NPA was 100% (95% CI 94.2 to 100%).Conclusion: Compared to the SHC-LDT, the Accula SARS-CoV-2 test showed excellent negative agreement. However, positive agreement was low for samples with low viral load. The false negative rate of the Accula POC test calls for a more thorough evaluation of POC test performance characteristics in clinical settings, and for confirmatory testing in individuals with moderate to high pre-test probability of SARS-CoV-2 who test negative on Accula.","J Clin Microbiol","Hogan, Catherine A","Garamani, Natasha","Lee, Andrew S","Tung, Jack K","Sahoo, Malaya K","Huang, ChunHong","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A","32461285"],"abstract":["Background: Several point-of-care (POC) molecular tests have received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for diagnosis of SARS-CoV-2. The test performance characteristics of the Accula (Mesa Biotech) SARS-CoV-2 POC test need to be evaluated to inform its optimal use.Objectives: The aim of this study was to assess test performance of the Accula SARS-CoV-2 test.Study design: The performance of the Accula test was assessed by comparing results of 100 nasopharyngeal swab samples previously characterized by the Stanford Health Care EUA laboratory-developed test (SHC-LDT) targeting the envelope (E) gene. Assay concordance was assessed by overall percent agreement, positive percent agreement (PPA), negative percent agreement (NPA), and Cohen's kappa coefficient.Results: Overall percent agreement between the assays was 84.0% (95% confidence interval [CI] 75.3 to 90.6%), PPA was 68.0% (95% CI 53.3 to 80.5%) and the kappa coefficient was 0.68 (95% CI 0.54 to 0.82). Sixteen specimens detected by the SHC-LDT were not detected by the Accula test, and showed low viral load burden with a median cycle threshold value of 37.7. NPA was 100% (95% CI 94.2 to 100%).Conclusion: Compared to the SHC-LDT, the Accula SARS-CoV-2 test showed excellent negative agreement. However, positive agreement was low for samples with low viral load. The false negative rate of the Accula POC test calls for a more thorough evaluation of POC test performance characteristics in clinical settings, and for confirmatory testing in individuals with moderate to high pre-test probability of SARS-CoV-2 who test negative on Accula."],"journal":"J Clin Microbiol","authors":["Hogan, Catherine A","Garamani, Natasha","Lee, Andrew S","Tung, Jack K","Sahoo, Malaya K","Huang, ChunHong","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461285","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1128/JCM.01072-20","topics":["Diagnosis"],"weight":1,"_version_":1668079521532739585,"score":314.1561}]}